Aldosterone and Mineralocorticoids

Hypertension

Volumn , Issue , 2005, Pages 117-122

  Funder, John W ^a,b,c  

^a MONASH UNIVERSITY   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149176355     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0258-5.50102-2     Document Type: Chapter

References (48)

1. Simpson S, Tait J, Wettstein A, et al. Isolierung eines neuen kristallisierten Hormons aus Nebennerien mit besonders hoher Wirksamkeit auf den Mineralsoffwechsel. Experientia 1953, 9:333-335.
2. Okubo S, Niimura F, Nishimura H, et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997, 99:855-860.
3. Rousseau G, Baxter J, Funder J, et al. Glucocorticoid and miner-alocorticoid receptors for aldosterone. J Steroid Biochem 1972, 3:219-227.
4. Funder JW, Pearce PT, Smith R, et al. Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 1989, 125:2224-2226.
5. Qin W, Rudolph A, Bond B, et al. A transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003, 93:69-76.
6. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268-275.
7. Greenwood A, Butler P, White R, et al. Multiple corticosteroid receptors in a teleost fish: Distinct sequences. Endocrinology 2003, 144:4226-4236.
8. Edwards CR, Stewart PM, Burt D, et al. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2:986-989.
9. Funder JW, Pearce P, Smith R, et al. Mineralocorticoid action: target-tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583-585.
10. Chen S, Bhargava A, Mastroberardino L, et al. Epithelial sodium channel regulated by aldosterone-induced protein SGK. Proc Natl Acad Sci USA 1999, 96:2514-2519.
11. Kornel L Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994, 7:100-103.
12. Alzamora R, Michea L, Marusic ET Role of 11beta-hydroxysteroid dehydrogenase on nongenomic aldosterone effects in human arteries. Hypertension 2000, 35:1099-1104.
13. Romagni P, Rossie F, Guerrini L, et al. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003, 166:345-349.
14. Gomez-Sanchez E, Funder J. Central mineralocorticoid receptors in the development of hypertension. Curr Opin Nephrol Hypertens in press, 2004.
15. Christ M, Douwes K, Eisen C, et al. Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension 1995, 25:117-125.
16. Mihailidou A, Mardini M, Funder JW Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C. Endocrinology 2004, 145:773-780.
17. Dunlop F, Crock P, Montalto J, et al. A compound heterozygote case of type II aldosterone synthase deficiency. J Clin Endocrinol Metab 2003, 88:2518-2526.
18. Lifton R, Dluhy R, Powers M, et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992, 2:66-74.
19. Conn J Primary aldosteronism: A new clinical syndrome. J Lab Clin Med 1955, 45:3-17.
20. Olivieri O, Ciacciarelli A, Signorelli D, et al. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab in press, 2004.
21. Armanini D, Kuhnle U, Strasser T, et al. Aldosterone-receptor deficiency in pseudohypoaldosteronism. New Engl J Med 1985, 313:1178-1181.
22. Komesaroff PA, Verity K, Fuller PJ Pseudohypoaldosteronism: molecular characterization of the mineralocorticoid receptors. J Clin Endocrinol Metab 1994, 79:27-31.
23. Zennaro M-C, Borensztein P, Jeunemaitre X, et al. No alteration in the primary structure of the mineralocorticoid receptors in a family with pseudohypoaldosteronism. J Clin Endocrinol Metab 1994, 79:32-38.
24. Geller D, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289:119-123.
25. New MI, Levine LS, Biglieri EG, et al. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977, 44:924-933.
26. Funder JW, Myles K Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996, 137:5264-5268.
27. Funder JW The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. Expert Opin Investig Drugs 2003, 12:1963-1969.
28. Funder JW Is aldosterone bad for the heart?. Trends Endocrinol Metab 2004, 15:139-142.
29. Lim P, Macdonald T, Holloway C, et al. Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. J Clin Endocrinol Metab 2002, 87:4398-4402.
30. Connell JM, Fraser R, MacKenzie SM, et al. The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation. Mol Cell Endocrinol 2004, 217:243-247.
31. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117-123.
32. Weinberger M, Roniker B, Krause S, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709-716.
33. Levy D, Rocha R, Funder JW Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004, 89:2736-2740.
34. Rocha R, Rudolph A, Frierdich G, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 2002, 283:H1802-H1810.
35. Chander P, Rocha R, Ranaudo J, et al. Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol 2003, 14:1990-1997.
36. Brilla CG, Weber KT Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893-901.
37. Young M, Fullerton M, Dilley R, et al. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578-2583.
38. Rocha R, Martin-Berger C, Yang P, et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143:4828-4836.
39. Sato A, Funder JW High glucose stimulates aldosterone-induced hypertrophy via Type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 1996, 137:4145-4153.
40. Zhang Q, Piston D, Goodman R Regulation of corepressor function by nuclear NADH. Science 2002, 295:1895-1897.
41. Fjeld C, Birdsong W, Goodman R Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci USA 2003, 100:9202-9207.
42. Young M, Moussa L, Dilley R, et al. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: Effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 2003, 144:1121-1125.
43. Ward MR, Kanellakis P, Ramsey D, et al. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001, 104(4):467-472.
44. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
45. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
46. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001, 103:72-77.
47. Tsutamoto T, Wada A, Maeda K, et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2000, 36:838-844.
48. Falkenstein E, Meyer C, Eisen C, et al. Full-length DNA sequence of a progesterone membrane-binding protein from porcine vascular smooth muscle cells. Biochem Biophys Res Commun 1996, 229:86-89.